Salvesen HB - Search Results

1

Plasma calprotectin concentrations in women with endometrial carcinoma.

Ni Bhriain H, Trovik J, Wik E, Stefansson IM, Akslen LA, Salvesen HB, Staff AC. Ni Bhriain H, et al. Among authors: salvesen hb. Gynecol Oncol. 2009 Sep;114(3):491-5. doi: 10.1016/j.ygyno.2009.06.008. Epub 2009 Jul 3. Gynecol Oncol. 2009. PMID: 19577278

2

Molecular pathogenesis and prognostic factors in endometrial carcinoma.

Salvesen HB, Akslen LA. Salvesen HB, et al. APMIS. 2002 Oct;110(10):673-89. doi: 10.1034/j.1600-0463.2002.1101001.x. APMIS. 2002. PMID: 12583434 Review.

3

Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas.

Engelsen IB, Stefansson I, Akslen LA, Salvesen HB. Engelsen IB, et al. Among authors: salvesen hb. Am J Obstet Gynecol. 2006 Oct;195(4):979-86. doi: 10.1016/j.ajog.2006.02.045. Epub 2006 May 3. Am J Obstet Gynecol. 2006. PMID: 16677592

4

HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas.

Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB. Engelsen IB, et al. Among authors: salvesen hb. Int J Oncol. 2008 Feb;32(2):307-16. Int J Oncol. 2008. PMID: 18202752

5

Biologic markers in endometrial cancer treatment.

Engelsen IB, Akslen LA, Salvesen HB. Engelsen IB, et al. Among authors: salvesen hb. APMIS. 2009 Oct;117(10):693-707. doi: 10.1111/j.1600-0463.2009.02467.x. APMIS. 2009. PMID: 19775337 Review.

6

Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting.

Wik E, Trovik J, Iversen OE, Engelsen IB, Stefansson IM, Vestrheim LC, Haugland HK, Akslen LA, Salvesen HB. Wik E, et al. Among authors: salvesen hb. Am J Obstet Gynecol. 2009 Dec;201(6):603.e1-7. doi: 10.1016/j.ajog.2009.07.029. Epub 2009 Oct 3. Am J Obstet Gynecol. 2009. PMID: 19800606

7

Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.

Trovik J, Wik E, Stefansson IM, Marcickiewicz J, Tingulstad S, Staff AC, Njolstad TS; MoMaTec Study Group; Vandenput I, Amant F, Akslen LA, Salvesen HB. Trovik J, et al. Among authors: salvesen hb. Clin Cancer Res. 2011 May 15;17(10):3368-77. doi: 10.1158/1078-0432.CCR-10-2412. Epub 2011 Jan 17. Clin Cancer Res. 2011. PMID: 21242118 Free article.

8

Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer.

Staff AC, Trovik J, Eriksson AG, Wik E, Wollert KC, Kempf T, Salvesen HB. Staff AC, et al. Among authors: salvesen hb. Clin Cancer Res. 2011 Jul 15;17(14):4825-33. doi: 10.1158/1078-0432.CCR-11-0715. Epub 2011 May 26. Clin Cancer Res. 2011. PMID: 21616994

9

Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective.

Trovik J, Mauland KK, Werner HM, Wik E, Helland H, Salvesen HB. Trovik J, et al. Among authors: salvesen hb. Gynecol Oncol. 2012 May;125(2):381-7. doi: 10.1016/j.ygyno.2012.01.050. Epub 2012 Feb 1. Gynecol Oncol. 2012. PMID: 22307064

10

Markers for individualised therapy in endometrial carcinoma.

Salvesen HB, Haldorsen IS, Trovik J. Salvesen HB, et al. Lancet Oncol. 2012 Aug;13(8):e353-61. doi: 10.1016/S1470-2045(12)70213-9. Lancet Oncol. 2012. PMID: 22846840 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

229 results

Search Page